Analysts Set BioNTech SE Sponsored ADR (NASDAQ:BNTX) Price Target at $133.73

BioNTech SE Sponsored ADR (NASDAQ:BNTX) has been assigned a consensus rating of “Moderate Buy” from the eighteen analysts that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and thirteen have assigned a buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $133.7333.

BNTX has been the subject of a number of recent research reports. Bank of America reissued a “buy” rating and issued a $128.00 target price on shares of BioNTech in a research report on Tuesday, March 10th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of BioNTech in a research note on Tuesday, March 17th. Wall Street Zen lowered BioNTech from a “hold” rating to a “sell” rating in a report on Saturday, March 14th. Citigroup lowered their price objective on BioNTech from $145.00 to $130.00 and set a “buy” rating on the stock in a research note on Wednesday, March 11th. Finally, Leerink Partners downgraded shares of BioNTech from an “outperform” rating to a “market perform” rating and set a $113.00 price objective on the stock. in a report on Monday, February 2nd.

BioNTech Trading Down 1.0%

Shares of BNTX stock opened at $88.41 on Tuesday. The company has a quick ratio of 7.49, a current ratio of 7.54 and a debt-to-equity ratio of 0.01. The firm has a market cap of $21.22 billion, a P/E ratio of -16.87 and a beta of 1.51. The company has a 50 day moving average of $105.36 and a 200-day moving average of $102.09. BioNTech has a 12-month low of $79.52 and a 12-month high of $124.00.

Institutional Trading of BioNTech

A number of institutional investors have recently modified their holdings of the business. Dodge & Cox grew its stake in BioNTech by 315.7% in the 3rd quarter. Dodge & Cox now owns 3,647,091 shares of the company’s stock valued at $359,676,000 after buying an additional 2,769,654 shares in the last quarter. GSK plc bought a new stake in BioNTech during the 4th quarter valued at $84,711,000. BNP Paribas Financial Markets lifted its position in shares of BioNTech by 43.0% during the fourth quarter. BNP Paribas Financial Markets now owns 1,578,094 shares of the company’s stock worth $150,235,000 after acquiring an additional 474,796 shares in the last quarter. Bank of America Corp DE lifted its position in shares of BioNTech by 344.4% during the third quarter. Bank of America Corp DE now owns 573,356 shares of the company’s stock worth $56,544,000 after acquiring an additional 444,332 shares in the last quarter. Finally, Voloridge Investment Management LLC bought a new position in shares of BioNTech in the fourth quarter worth $41,656,000. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

BioNTech Company Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.